+34.0%
CLSK vs MRNA
+485.7%
-451.7%
-64.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.8% | +5.4% | +1.4% | +6.6% |
| 7D | +7.7% | -1.1% | +8.8% | +7.8% |
| 30D | +12.2% | +126.1% | -113.9% | +4.5% |
| 3M | -15.5% | +190.0% | -205.5% | -30.2% |
| 6M | +39.3% | +157.2% | -117.9% | +19.6% |
| YTD | +35.1% | +388.2% | -353.1% | -9.9% |
| 1Y | +34.0% | +467.0% | -433.0% | -11.4% |
| All | +34.0% | +485.7% | -451.7% | -11.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling